N-acetylneuraminate pyruvate lyase (NPL)

N-acetylneuraminate pyruvate lyase (NPL), also known as N-acetylneuraminate lyase or N-acetylneuraminic acid aldolase, is an enzyme that catalyzes the reversible cleavage of N-acetylneuraminic acid (sialic acid, Neu5Ac) into N-acetylmannosamine and pyruvate[5][6][7]. It belongs to the lyase family, specifically the oxo-acid-lyases (EC 4.1.3.3), and features a characteristic (beta/alpha)_8 TIM-barrel fold[2][3][6]. The catalytic activity involves formation of a Schiff base intermediate between a conserved lysine in the active site and the substrate[1][2][3]. NPL is biologically important in bacterial sialic acid metabolism, facilitating both nutrient acquisition and immune evasion in pathogenic microorganisms[2]. This enzyme has been studied across a range of bacterial species and is also present in humans[4]. Its structural properties and catalytic mechanism have enabled extensive biochemical and crystallographic analysis, and it is utilized in biotechnological synthesis of sialic acids[7]. While not currently a direct therapeutic target, it represents a potential avenue for antimicrobial drug development, particularly in the context of inhibiting pathogen use of host sialic acid[2].

Other names

N-acetylneuraminate lyaseNPLC1orf13NALaseNPL1DHDPS1N-acetylneuraminate pyruvate-lyaseN-acetylneuraminic acid aldolaseSialate lyaseSialate-pyruvate lyaseSialic acid aldolaseSialic acid lyaseDihydrodipicolinate synthetase homolog 1 (E. coli)C112NALNalaseDihydrodipicolinate synthetase homolog 1

Prospectively, inhibitors would block the enzyme's catalytic activity (usually targeting Schiff base formation step or substrate binding). No established clinical pharmacology.